Integumen's Labskin signs three new R&D agreements
Francesca Morgan
Company News - 2 mins
09:56, 7th November 2019

Vertically integrated product and services firm, Integumen (SKIN)  FOLLOW, announced on Thursday that its Labskin subsidiary had signed microbiome R&D agreements with three Top 20 global cosmetic companies.

The agreements are worth an aggregated low six-figure value, to be completed over the next four months, the company explained.

The firm will provide the first commercially available combination of cloned Labskin, microbiome tests and gene sequencing using data analytics on the LabskinAI platform.

These tests are expected to confirm the impact of the clients' new products and ingredients on human skin.

The company further explained that with the addition of three new R&D agreements, the firm remains on track to exceed £1m revenue by the end of the year.

Alongside this, additional R&D service agreements from all three clients are expected to follow on after initial trials are completed.

“Each breakthrough and combination of cloned skin microbiome definition for diseased skin and the data analytic use of AI on the gene sequencing results, without any harm to animals, builds the unique offering of the enlarged Group,” said Integumen’s Chief Executive, Gerard Brandon.

He added, “This is why we believe that providing world class services to our prestigious client base in the skin care and cosmetic industries will continue to provide strong growth and new contract revenues into 2020, and ultimately, drive value for our shareholders."

The company further added that their range of test services, with an extension to include R&D support, will be conducted at the firm’s new, enlarged laboratories in York, UK.

Follow News & Updates from Integumen here: FOLLOW

Disclaimer & Declaration of Interest

The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.

Comments
info
Login or register to post comments

Recent Articles
Watchlist